Lyra Therapeutics Inc (NAS:LYRA)
$ 0.2952 -0.0149 (-4.8%) Market Cap: 18.00 Mil Enterprise Value: -31.26 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 29/100

Lyra Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript

Jul 15, 2021 / 02:00PM GMT
Release Date Price: $7.45 (-1.72%)
Lachlan Hanbury;Brown
William Blair - Analyst

Thank you everyone for joining us today. My name is Lachlan Hanbury-Brown; I am an associate on the biotech team here at Blair supporting Tim Lugo. It's my pleasure to have with me today, Dr. Maria Palasis, President and CEO of Lyra Therapeutics for a fireside chat.

Before we get started, I wanted to remind everyone to please visit our website, williamblair.com, for a complete list of research disclosures and potential conflicts of interest; and also please feel free to submit any questions you have through the Q&A feature of the webinar and I will try to get to them as we work our way through the discussion.

So with that out of the way, I will hand it off to Maria to give us an overview of the Company.

Maria Palasis
Lyra Therapeutics Inc. - President & CEO

Great. Hi, Lachlan. Thank you for the introduction and hope you're doing well this morning. So Lyra Therapeutics is in a position to dominate the ENT treatment of chronic rhinosinusitis. We estimate that to be a $6

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot